Questcor Pharmaceuticals Reports Q1 Gross Sales of $48.6M

Questcor Pharmaceuticals, Inc. QCOR today announced preliminary operating metrics for its first quarter ended March 31, 2011. New, paid prescriptions of H.P. Acthar® Gel for the treatment of exacerbations of multiple sclerosis during the quarter were greater than 500, up over 115% from the year ago period and up over 40% from the prior quarter. New, paid prescriptions for infantile spasms were estimated at 88. New, paid prescriptions for nephrotic syndrome were estimated at 18. 2,010 vials of the Company's principal drug, Acthar, were shipped during the quarter ended March 31, 2011. Gross sales were $48.6 million.